USFDA issues EIR for Shilpa Medicare's R&D unit in Andra Pradesh

Image
Capital Market
Last Updated : Apr 22 2019 | 10:31 AM IST
Shilpa Medicare announced that that the Pharmaceutical Research & Development Unit of the Company situated at Modavalasa, Vizianagaram (Dt), Andhra Pradesh region has received U.S FDA Establishment Inspection Report (EIR) with intimation of closure of inspection on 08 April 2019.

This R&D site has undergone an inspection by the USFDA during 11 February 2019 to 13 February 2019, wherein the company was issued a Form 483 with 1 (one) observation. Based on its responses and follow up actions, the USFDA has determined the inspection classification of this facility as Voluntary Action Initiated (VAI).

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 22 2019 | 10:23 AM IST

Next Story